As February begins, we review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and categories on BPIQ.com compared to XBI.
Table 1. BPIQ company weekly moves and YTD moves
Highlights for the week of 1/31 - 2/4
Biggest positive moves
$VCNX +46.02%; on a rise since last week when Vaccinex Announces $6.6 Million Private Placement
$SCPH +35.0%; scPharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference
Biggest negative moves
Additional big moves
$CLSN +18.1%; advancing SARS-CoV-2 proof of concept trial
$HUMA +15.7%; clinical case series data reported
$NVAX +13.0%; FDA EUA request submitted
$RETA +12.9%; rolling submission of NDA initiated
$CRTX +12.3%; anticipated 2022 milestones announced
$GLSI +12.1%; Ph3 FLAMINGO-01 update
$ALT +12.1%; FDA clearance of pemvidutide
$TARS -14.2%; Ph3 Saturn-2 trial updates
$VNDA -18.2%; results from Ph3 Tradipitant trial
Highlights for next week
$PASG PBGM01 Phase ½ additional data readout
Watch over the next few weeks for quarterly company reports including commercial sales
See our Big Movers post to learn about the upcoming Feb Big Movers/Movers to Watch
Comments